No association between deletion-type angiotensin-converting enzyme gene polymorphism and left-ventricular hypertrophy in hemodialysis patients

Nephron

Volumn 84, Issue 2, 2000, Pages 130-135

  Yildiz, Alaattin ^a,c   Akkaya, Vakur ^a   Hatemi, Ali Can ^a   Çine, Naci ^a   Tükek, Tufan ^a   Görçin, Bilal ^b   Demirel, Şeref ^a   Türk, Süleyman ^a   Sever, Mehmet Ş ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Turkish Kidney Foundation   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Angiotensin converting enzyme polymorphism; Hemodialysis; Left ventricular hypertrophy; Renal disease

Indexed keywords

ALBUMIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; HEMOGLOBIN;

ADULT; ANEMIA; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TIME;

EID: 0033976836     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045560     Document Type: Article

References (37)

1. Castellano M, Muiesan L, Rizzoni D, et al: Angiotensin converting enzyme I/D polymorphism and arterial wall thickness in a general population. The Vobarno Study. Circulation 1995;91:2721-2724.
2. Schunkert H, Hense H-W, Holmer SR, et al: Association between a deletion polymorphism of the angiotensin converting enzyme gene and left ventricular hypertrophy. N Engl J Med 1994;330-1634-1638.
3. Lindpaintner K, Lee M, Larson MG, et al: Absence of association or genetic linkage between the angiotensin converting enzyme gene and left ventricular mass. N Engl J Med 1996; 334:1023-1028.
4. Parfrey PS, Foley RN, Harnett JD, et al: The outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 1996;11:1277-1285.
5. Harnett JD, Kent KM, Barre PE, et al: Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994;4: 1486-1490.
6. London GM, Parfrey PS: Cardiac disease in chronic uremia: Pathogenesis. Adv Renal Rephae Ther 1997;4:194-211.
7. Perloff D, Grimm C, Flack J, et al: AHA Medical/Scientific Statement: Human Blood Pressure Determination by Sphygomomanometry. Circulation 1993;88 (5 Pt 1):2460-2470.
8. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNCV). Arch Intern Med 1993;153:154-183.
9. Declaration of Helsinki: Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects. 41th World Medical Assembly, Hong Kong, September, 1989.
10. Henry WL, DeMaria A, Gramiak R, et al: Report of the American Society of Echocardiography Committee on nomenclature and standards in two-dimensional echocardiography. Circulation 1980;62:212-217.
11. Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding quantilation in M mode echocardiographic measurements. Circulation 1978;58:1072-1083.
12. Devereux RB, Koren NJ, deSimone P, Okin N, Klingfield P: Methods for detection of left ventricular hypertrophy: Application to hypertensive heart disease. Eur Heart J 1993;14(suppl D):8-15.
13. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in men. Anatomic validation of the method. Circulation 1977;55:613-618.
14. Miller SA. Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
15. Rigat B, Hubert C, Corvol P, Soubrier F: PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCPI) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992;20:1433.
16. Silberberg JS, Barre P, Prichard S, et al: Impact of left ventricular hypertrophy on survival in end stage renal disease. Kidney Int 1989;36: 286-290.
17. US Renal Data System: Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients. Am J Kidney Dis 1992;20:32-38.
18. Foley RN, Parfrey PS, Harnet JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192.
19. Parfrey PS: Pathogenesis of cardiac disease in dialysis patients. Semin Dial 1999;12:62-68.
20. Foley RN, Parfrey PS, Harnett JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-195.
21. Foley RN, Parfrey PS, Harnett JD, et al: Hypoalbuminemia, cardiac morbidity and mortality in end stage renal disease. J Am Soc Nephrol 1996;7:728-736.
22. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-1513.
23. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P: Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998;13:564-569.
24. London GM, Pannier B, Guerin AP, Marchais, SJ, Safar ME, Cuche JL: Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994;96: 2786-2796.
25. Dyadyk AI, Bagriy AE, Lebed IA, Yarovaya NF, Schukina EV, Taradin GG: ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant 1997;12:945-951.
26. Schunkert H, Hense HW, Muscholl M, et al: Association between circulating components of renin-angiotensin-aldosterone system and left ventricular mass. Heart 1997;77:24-31.
27. Cannella G, Pauletti E, Delfino R, Peloso G, Rolla D, Molinari S: Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997;30:659-664.
28. Rigat B, Hubert C, Alhenge-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86: 1343-1346.
29. Iwai N, Ohmichi N, Nakamura Y, Kinoshita M: DD genotype of the Angiotensin Converting enzyme gene is a risk factor for left ventricular hypertrophy. Circulation 1994;90:2622-2628.
30. Osono E, Kurihara S, Hayama N, et al: Insertion/deletion polymorphism in intron 16 of the ACE gene and left ventricular hypertrophy in patients with end-stage renal disease. Am J Kidney Dis 1998;32:725-730.
31. Nagahara T, Ishigami T, Sano T, et al: Angiotensin-converting enzyme gene insertion/deletion polymorphism and left ventricular hypertrophy in hemodialysis patients. Jpn Heart J 1997;38:821-830.
32. Schmidt A, Kiener HP, Barnas U, et al: Angiotensin-converting enzyme polymorphism in patients with terminal renal failure. J Am Soc Nephrol 1996;7:314-317.
33. Ruzicka M, Leenen FH: Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. Circulation 1995;91:16-19.
34. Schunkert H, Jackson B, Tang SS, et al: Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 1993;87:1328-1339.
35. Hunley TE, Julian BA, Phillips JA, et al: Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression of IgA nephropathy. Kidney Int 1996;49: 571-577.
36. Fernandez-Llama P, Poch E, Oriola J, et al: Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis. Kidney Int 1998;53:1743-1747.
37. Marre M, Bernadet P, Galois Y, et al: Relationship between angiotensin I converting enzyme gene polymorphism, plasma levels and diabetic retinal and renal complications. Diabetes 1994; 43:384-388.